Videos

Stacey Rifkin-Zenenberg, DO, on early gene therapy outcomes and the long-term questions still being tracked in sickle cell disease.

A Stanford dermatologist explains how AI systems can reinforce racial bias in health care and underperform on skin cancer detection in darker skin.

Robert Wood, MD, of Johns Hopkins University explains what the July 31 exit means for peanut oral immunotherapy and omalizumab-assisted desensitization.

Meagen McCusker, MD, discusses trusting instinct over rigid planning and why female physicians should lean on each other during career transitions.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline data from the TRIUMPH-3 trial of retatrutide.

Mandana Khalili, MD, discusses how baseline motivation predicted alcohol reduction in a stepped treatment trial for liver disease patients.

Friedman breaks down the updated CSU guidelines and where omalizumab, dupilumab, and remibrutinib fit.

In this segment from the latest episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, discuss the topline results of the TRIUMPH-2 trial of retatrutide.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the risks of ordering GLP-1 RAs online.

Anderson discusses recent advancements in CGM technology, as well as the myriad behavioral and clinical benefits of CGM use in T2D with or without insulin.

New STOP-HS trial data show durable povorcitinib response through week 54, with a favorable safety profile in hidradenitis suppurativa.

Martina Porter, MD, discusses new STOP-HS trial data on povorcitinib, the first oral phase 3 therapy for hidradenitis suppurativa.

July saw some of the biggest FDA approvals so far in 2026 – catch up on what you might have missed!

Linda Stein Gold, MD, explains what new ADORING data reveal about tapinarof cream for atopic dermatitis across age cohorts.

New phase 3 data show tapinarof cream (VTAMA) delivered early, consistent efficacy across pediatric and adult age groups with atopic dermatitis.

As Palforzia exits the market on July 31, 2026, allergists Robert Wood, MD, and Jacqueline Ross, MD, outline what changes for patients already in treatment.

Lebrikizumab improved itch, quality of life, and infection rates in kids with moderate-to-severe atopic dermatitis, ADorable-1 results suggest.

New phase 3 ADorable-1 data show lebrikizumab improved skin clearance in children with moderate-to-severe atopic dermatitis.

Benjamin van Boxtel, MD, discusses the importance of familial screening for aortic dissection and the danger of missing potential risk factors.

Robert Wood, MD, discusses OUTMATCH data showing omalizumab beat multiallergen oral immunotherapy, though MOIT dropouts narrowed the gap.

Bryan Wells, MD, breaks down new data from 3 universities that have produced a relatively consistent peak systolic velocity, indicating the potential for broad treatment guidelines.

New FARE registry data show epinephrine use and biphasic reactions occur across sesame, seed, and herb/spice allergies, according to Carolyn H. Baloh, MD.

In this episode of The Medical Sisterhood, physician entrepreneurship is explored as Meagen McCusker, MD, shares lessons on private practice, leadership, and career.

Hunter Champion, MD, PhD, covers his experience with furosemide injections in reducing hospital readmissions and how the ReadyFlow may decrease them further.

A FARE Patient Registry analysis finds herb and spice allergies disproportionately affect Black, Hispanic, and lower-income patients, Carolyn Baloh, MD, says.

How is drug selection evolving in atopic dermatitis? Walter Liszewski, MD, discusses personalized therapy and long-term care.

Mohammed Chowdhury, MD, a Temple University cardiologist, says the field is 2 to 5 years from routine clinical integration — but validation and insurance coverage remain the critical hurdles.

FDA approves Freenome's SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults aged 45 years and older.